Wave Life Sciences

Wave Life Sciences

Wave Life Sciences is a biotechnology company developing therapies to treat genetic diseases.

Wave Life Sciences is a publicly traded biotechnology company based in Cambridge, Massachusetts. It focuses on designing, developing, and commercializing stereopure nucleic acid therapeutics that precisely targets the underlying cause of rare genetic diseases through its proprietary synthetic chemistry drug development platform.

The company's pipeline initially focused on neurological disorders and later extended across several other therapeutic areas including, muscular, opthalmology, and hephatic disorders. In the central nervous system category, Wave Life Sciences is developing treatments for Huntington's disease, amyotrophic lateral sclerosis, frontotemporal dementia, spinocerebellar ataxia 3, and other CNS diseases. Of these, two therapies focused on Huntington's disease is in Phase 1b/2a clinical trials, while the therapies for the other conditions are in pre-clinical stages. Commercial rights for these are shared with Takeda.

The company's pipeline also has several possible therapies for Duchenne muscular dystrophy and other neuromuscular diseases. Of these, one therapy for Duchenne muscular dystrophy has entered Phase 1 clinical trials with the rest in various pre-clinical stages. Wave Life also has a couple of product candidates in the discovery stage focusing on retinal diseases and metabolic liver diseases. Of these, the latter is in partnership with Pfizer.

Timeline

People

Name
Role
LinkedIn

Chandra Vargeese

Senior VP, Drug Discovery

Chris Francis

Senior VP, Corporate Development & Head of Emerging Areas

Clare Carmichael

Chief Human Resources Officer

J. Keith McElveen

Employee

Jose Juves

VP, Public Affairs

Keith Regnante

CFO

Kyle Moran

Senior VP, Operations & Business Analytics

Linda Rockett

General Counsel

Michael Panzara

Chief Medical Officer

Noah Schiffman

Employee

Paul Bolno

President & CEO

Tushar Misra

Senior VP, Technical Operations

Wendy Erler

VP, Patient Advocacy and Market Insights

Further reading

Title
Author
Link
Type
Date

Cambridge-Based Wave Life Sciences Expands Into New Facility Designed to House Up to 200 Employees | BioSpace

Alex Keown

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
March 30, 2021
FierceBiotech
Just over a year after Wave Life Sciences cut staffers, threw out a Duchenne muscular dystrophy med and saw its Huntington's disease drug flop in a key test, the waves come crashing down again for the biotech.
BioSpace
May 18, 2020
BioSpace
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has appointed Kenneth Rhodes, PhD, as Senior Vice President, Therapeutics Discovery. In this newly created position, Dr. Rhodes will be responsible for defining the strategy and guiding discovery research to design new therapeutic candidates and adva
Skyhawk Therapeutics
Invalid Date
www.prnewswire.com:443
Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.